FDA clears MiniMed Fit tubeless insulin pump; Eversense 365 pairs with iLet; JAMA summit lays out obesity actions

An insulin pen lying at a slight angle with its cap beside it, showing a clear cartridge window and a dose knob with plain tick marks.

The Food and Drug Administration (FDA) cleared MiniMed Fit, the company's first tubeless insulin pump, for people with type 1 and type 2 diabetes ages 7 and older, MiniMed said Nov. 16. Senseonics and Beta Bionics launched pairing of the year-long Eversense 365 sensor with the iLet Bionic Pancreas, a JAMA summit report proposed obesity policy and care actions, and a trial of psychologist care in type 1 diabetes eased distress without a significant HbA1c change.

The weekly innovation roundup for endocrinology, published every Sunday for the week before; every item links to its sources. Latest endocrinology news · All specialties

Latest news

Tagged endocrinology, from the daily briefing

  1. FDA approves a once-weekly insulin for type 2 diabetes in children, JAMA reports
  2. Randomized trial in 151 adults with type 1 diabetes tests adding a diabetes-educated psychologist to usual care
  3. Cohort study compares GLP-1 drugs, tirzepatide and tezepelumab for obesity-associated asthma without diabetes

See all the latest news